The University of Nottingham has successfully spun out 40 companies.
Our Technology Transfer Office is based at the Sir Colin Campbell Building which provides a gateway between Jubilee Campus and the University's Business Park (UNIP), and acts as an incubator for high technology companies, mainly in physical sciences.
University of Nottingham spin-outs also benefit from the incubation facilities provided by BioCity, Nottingham, the largest bioincubator in the UK, which is uniquely structured to focus on bioscience and healthcare companies.
Below is a selection of the University’s spin-out and commercial subsidiary companies with a brief description of what they do.
Further information about our spin-out activities is available in the Spin-out Company Portfolio brochure or by emailing firstname.lastname@example.org.
Added Scientific is a service and consultancy facility operating out of the Additive Manufacturing section within the Faculty of Engineering, focusing on design, bespoke software, material development, process enhancement and characterisation of product materials in additive manufacturing and 3D printing.
Critical Pharmaceuticals is a drug delivery product development company. It has developed a simple, one-step, patented formulation process to create a highly active drug delivery system. Based in BioCity, Nottingham, Critical Pharmaceuticals has received both seedcorn and venture-capital funding.
Heartlight Systems is a joint venture business between The University of Nottingham and Tioga Ltd, an electronics manufacturing company with an international reputation, to further develop the University's Heartlight technology - a novel method of measuring heart rate by using changes in reflected light from the skin.
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as paint control, macular degeneration and cancer. Anti-VEGF-directed therapy currently constitutes the gold-standard treatment for Age Related Macular Degeneration (AMD) and other neovascular diseases of the eye.
Exonate's research in this area has identified therapeutic candidates for wet AMD that can be administered as a simple eye drop, thereby overcoming the unpleasant need for once-a-month injections in the eye.
Founded in 1997 by an academic group at The University of Nottingham, Molecular Profiles was set up to provide drug development and consulting services to the pharmaceutical industry worldwide.
In September 2013 the company was acquired by Columbia Laboratories Inc (Nasdaq: CBRX) of Boston. In April 2015 Columbia Laboratories announced that the company had adopted Juniper Pharma Services as its new brand name.
Acquisition of Molecular Profiles by Columbia Laboratories
Molecular Profiles is now Juniper Pharmaceuticals
Monica Healthcare was formed following 15 years of collaborative research between the University's School of Electrical and Electronic Engineering and its Department of Obstetrics.
The company has devised technologies for foetal and maternal heart monitoring using electrophysiological systems that provide improved and constant monitoring through a simple wearable device, which offers significant benefits over existing systems Its products are now being used in hospitals throughout the world.
Oncimmune has developed EarlyCDT-Lung – a blood test that aids the risk assessment and early detection of lung cancer. This breakthrough is being extended to the detection of other common cancers e.g. breast, colorectal, ovarian and prostate. The company is based in customised laboratory and office space at Nottingham City Hospital and has attracted significant private investment.
PRECOS (Pre Clinical Oncology Services) Ltd offers specialised research services in preclinical oncology testing. The University established PRECOS as a specialist business unit in 2004, and it was spun-out as a separate company in 2010.
In July 2013 the company was acquired by American bioscience business, Crown Bioscience Inc.
Promethean Particles expertise lies in the development of an original process for nanoparticle production which is based on research from the University’s School of Chemical and Environmental Engineering. Its underpinning technology, the SWiNG reactor, was fully developed at the University. The company is based in Nottingham Science Park and has received seedcorn investment.
Scancell specialises in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer. Its four main research areas are: apoptosis-inducing monoclonal antibodies; anti-growth factor antibodies; identification of novel antigens, and vaccine development.
Spin-outs by discipline
Spin-out Company Portfolio brochure 2014
New spin-out companies 2014/15
Sir Colin Campbell BuildingUniversity of Nottingham Innovation ParkTriumph Road
Nottingham, NG7 2TU
telephone: +44 (0) 115 748 4555
fax: +44 (0) 115 823 2181
Connect with The University of Nottingham through social media and our blogs.
Campus maps | More contact information | Jobs
Browser does not support script.